Woodline Partners LP Invests $991,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)

Woodline Partners LP purchased a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 135,036 shares of the company's stock, valued at approximately $991,000. Woodline Partners LP owned about 0.10% of Vir Biotechnology as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Vir Biotechnology by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company's stock worth $16,127,000 after buying an additional 7,827 shares during the period. Dimensional Fund Advisors LP increased its stake in Vir Biotechnology by 58.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock worth $14,059,000 after buying an additional 703,360 shares during the period. Millennium Management LLC increased its stake in Vir Biotechnology by 55.3% during the 4th quarter. Millennium Management LLC now owns 1,715,083 shares of the company's stock worth $12,589,000 after buying an additional 610,367 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Vir Biotechnology by 10.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company's stock worth $9,194,000 after buying an additional 118,379 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Vir Biotechnology by 4.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,237,600 shares of the company's stock worth $9,084,000 after buying an additional 55,300 shares during the period. Institutional investors and hedge funds own 65.32% of the company's stock.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR traded down $0.33 during trading on Friday, reaching $4.86. 2,399,232 shares of the company's stock traded hands, compared to its average volume of 1,398,514. Vir Biotechnology, Inc. has a 12 month low of $4.32 and a 12 month high of $14.45. The company has a 50 day moving average of $5.50 and a 200-day moving average of $7.51. The stock has a market capitalization of $671.84 million, a P/E ratio of -1.24 and a beta of 1.36.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $3.03 million for the quarter, compared to the consensus estimate of $8.59 million. During the same period in the prior year, the company earned ($0.48) EPS. Vir Biotechnology's quarterly revenue was down 94.6% on a year-over-year basis. Equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

VIR has been the topic of several analyst reports. Barclays lifted their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. HC Wainwright reissued a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. The Goldman Sachs Group dropped their target price on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $14.00 target price on shares of Vir Biotechnology in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $32.86.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the transaction, the chief executive officer now directly owns 769,505 shares of the company's stock, valued at $4,578,554.75. The trade was a 9.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 16.00% of the stock is currently owned by company insiders.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).